A Rapamycin Derivative For Treating Lung Cancer

A compound, 40-O-(2-hydroxyethyl)-rapamycin, for treating solid tumors, particularly lung cancer, by inhibiting angiogenesis and tumor growth. The compound, a derivative of the macrolide antibiotic rapamycin, selectively targets endothelial cells and suppresses their proliferation, particularly in response to vascular endothelial growth factor (VEGF). It exhibits antitumor activity in preclinical models, including human lung and epidermoid tumor xenografts, and shows potential for combination therapy with conventional anticancer agents.